XSNX Projected Dividend Yield
NovAccess Global Inc ( OTCBB : XSNX )NovAccess Global is a biopharmaceutical company that is developing immunotherapies to treat brain tumor patients in the U.S. Co. focuses in the research and development of a new drug to treat brain cancer and other cancers. Co. performs pre-clinical and clinical trial experiments to bring the drugs to market. Co.'s dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor (TLR) adjuvants for an improved anti-tumor response. The therapy is designed to utilize the patient's tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an anti-tumor immune response. 20 YEAR PERFORMANCE RESULTS |
XSNX Dividend History Detail XSNX Dividend News XSNX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |